Factors associated with success of telaprevir- and boceprevir-based triple therapy for hepatitis C virus infection

Table 3 Comparison of on-treatment variables in the sustained virologic response and non- sustained virologic response group

	Total cohort Categorical: n (%) Continous: Median (IQR)	SVR (n = 94)	Fail to achieve SVR (n = 129)	P
Discontinuation due to adverse events	44/223 (20%)	13/94 (14%)	31/94 (24%)	0.06a
Change in ferritin from baseline to week 4 of treatment, ng/mL	91 (45-212)	146 (81-331)	62 (-20-175)	0.08b
Development of severe anemia	94/223 (42%)	54/94 (57%)	66/129 (51%)	0.35a
Change in eGFR from baseline to week 4c, mL/min per 1.73 m2	-4.41 (-14.87-3.23)	-6.59 (-16.98-0.52)	-1.68 (-13.99-5.00)	0.04b
Fast viral kinetics	139/223 (62%)	83/94 (88%)	56/129 (43%)	< 0.01a

^aχ² test;

^b Mann-Whitney test;

^c Estimated glomerular filtration rate calculated with epidemiology formula. SVR: Sustained virological response; eGFR: Estimated glomerular filtration rate.